Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 5
1984 6
1985 17
1986 21
1987 19
1988 36
1989 31
1990 38
1991 41
1992 37
1993 28
1994 29
1995 43
1996 36
1997 43
1998 33
1999 33
2000 43
2001 42
2002 42
2003 36
2004 46
2005 28
2006 45
2007 50
2008 47
2009 47
2010 49
2011 59
2012 47
2013 59
2014 62
2015 76
2016 68
2017 57
2018 68
2019 60
2020 50
2021 57
2022 57
2023 48
2024 52
2025 69
2026 52

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,762 results

Results by year

Filters applied: . Clear all
Page 1
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Morelli A, et al. JAMA. 2013 Oct 23;310(16):1683-91. doi: 10.1001/jama.2013.278477. JAMA. 2013. PMID: 24108526 Clinical Trial.
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = .02), whereas the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the control group (IQR, -2 t …
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = . …
Esmolol.
Ramsay JG. Ramsay JG. Can J Anaesth. 1991 Mar;38(2):155-8. doi: 10.1007/BF03008136. Can J Anaesth. 1991. PMID: 1673642 English, French. No abstract available.
Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
Bahr MP, Williams BA. Bahr MP, et al. Reg Anesth Pain Med. 2018 Nov;43(8):815-818. doi: 10.1097/AAP.0000000000000873. Reg Anesth Pain Med. 2018. PMID: 30216240 Review.
beta-Adrenergic blockade is an important mechanism for reducing morbidity and mortality in patients with hypertension and heart failure. Esmolol has been used widely for its chronotropic and antihypertensive effects. However, there has been recent inquiry regarding periope …
beta-Adrenergic blockade is an important mechanism for reducing morbidity and mortality in patients with hypertension and heart failure. …
The role of esmolol in sepsis: a meta-analysis based on randomized controlled trials.
Wei Y, Bo F, Wang J, Fu J, Qiu Y, Bi H, He D, Liu X. Wei Y, et al. BMC Anesthesiol. 2024 Sep 12;24(1):326. doi: 10.1186/s12871-024-02714-3. BMC Anesthesiol. 2024. PMID: 39266951 Free PMC article.
Keywords and free words of 'sepsis', 'esmolol' and 'randomized controlled trials' were used for search. Meta-analysis was performed using RevMan 5.3 software. ...CONCLUSION: Esmolol reduces 28-day mortality, length of ICU stay and duration of mechanical ventilation …
Keywords and free words of 'sepsis', 'esmolol' and 'randomized controlled trials' were used for search. Meta-analysis was performed u …
Clinical pharmacokinetics and therapeutic efficacy of esmolol.
Wiest DB, Haney JS. Wiest DB, et al. Clin Pharmacokinet. 2012 Jun 1;51(6):347-56. doi: 10.2165/11631590-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22515557 Review.
Since our previous review in 1995, the pharmacokinetics and efficacy of esmolol have been investigated in a number of acute care settings. Three studies investigated the pharmacokinetics and safety of esmolol in the paediatric population. ...For postoperative patien …
Since our previous review in 1995, the pharmacokinetics and efficacy of esmolol have been investigated in a number of acute care sett …
Esmolol-digoxin drug interaction.
Lowenthal DT, Porter RS, Achari R, Turlapaty P, Laddu AR, Matier WL. Lowenthal DT, et al. J Clin Pharmacol. 1987 Aug;27(8):561-6. doi: 10.1002/j.1552-4604.1987.tb03067.x. J Clin Pharmacol. 1987. PMID: 2888792
Digoxin peak concentration and the time to reach the peak concentration were not affected by esmolol. However, the digoxin AUC during the six-hour esmolol infusion increased from 2.60 +/- 0.59 to 2.88 +/- 0.75 ng.hr/mL (P less than .05). ...The PR intervals were sim …
Digoxin peak concentration and the time to reach the peak concentration were not affected by esmolol. However, the digoxin AUC during …
Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
Wiest D. Wiest D. Clin Pharmacokinet. 1995 Mar;28(3):190-202. doi: 10.2165/00003088-199528030-00002. Clin Pharmacokinet. 1995. PMID: 7758250 Review.
Full recovery from beta-blockade is observed 18 to 30 minutes after terminating the infusion. Esmolol blood concentrations are undetectable 20 to 30 minutes postinfusion. The elimination of esmolol is independent of renal or hepatic function as it is metabolised by …
Full recovery from beta-blockade is observed 18 to 30 minutes after terminating the infusion. Esmolol blood concentrations are undete …
Electrophysiology of esmolol.
Greenspan AM, Spielman SR, Horowitz LN, Senior S, Steck J, Laddu A. Greenspan AM, et al. Am J Cardiol. 1985 Oct 23;56(11):19F-26F. doi: 10.1016/0002-9149(85)90912-9. Am J Cardiol. 1985. PMID: 2864844
The electrophysiologic characteristics of esmolol were studied in 14 patients. Ten men and 4 women, mean age 57 years, were electrophysiologically evaluated at baseline, and also at 4 to 8 minutes after the administration of a maintenance infusion of esmolol. Plasma …
The electrophysiologic characteristics of esmolol were studied in 14 patients. Ten men and 4 women, mean age 57 years, were electroph …
Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database.
Liang Q, Li L, Chen K, An S, Deng Z, Li J, Zhou S, Chen Z, Zeng Z, An S. Liang Q, et al. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231185985. doi: 10.1177/10742484231185985. J Cardiovasc Pharmacol Ther. 2023. PMID: 37415421 Free article.
BACKGROUND AND AIMS: Esmolol is a common short-acting drug to control ventricular rate. This study aimed to evaluate the association between use of esmolol and mortality in critically ill patients. ...Patients in esmolol group showed no significant difference …
BACKGROUND AND AIMS: Esmolol is a common short-acting drug to control ventricular rate. This study aimed to evaluate the association …
1,762 results